Skip to content
Bored Studies
RecruitingPhase 3

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Sun Pharmaceutical Industries, Inc. · NCT07133308

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 12–17 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
355
US sites recruiting
54
Study start
August 5, 2025
Record last updated
January 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

Being studied: Deuruxolitinib; Placebo

Conditions: Alopecia Areata

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years.
  • Between 12 to \<18 years of age
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50.
  • Willing to comply with the study visits and requirements of the study protocol

Exclusion Criteria

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and/or Baseline
  • Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response.
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
  • Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

Recruiting US locations

Study contacts (from the official record)

  • Head Regulatory Affairs · 9122 66455645 · Clinical.Trial@sunpharma.com
All dermatology studies in Alabama →
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in… (NCT07133308) | Bored Studies